KRAS and non-small cell lung carcinoma: In the KRYSTAL-1 trial, adagrasib showed an ORR of 35.1% and mPFS of 7.4 months in KRAS G12C-mutated tumors excluding NSCLC and CRC (NCT03785249) [95].